Microalbuminuria: Cardiovascular and renal risk factors underestimated in clinical practice;Microalbuminúria: Fator de risco cardiovascular e renal subestimado na prática clínica

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 50, Issue 2, 2006, Pages 313-321

  Zanella, Maria Teresa ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Cardiovascular protection; Cardiovascular risk; Microalbuminuria; Renal protection

Indexed keywords

ALBUMINOID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ALBUMINURIA; CARDIOVASCULAR DISEASE; DIABETIC NEPHROPATHY; HUMAN; HYPERTENSION; KIDNEY DISEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; URINE;

ALBUMINS; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION; KIDNEY DISEASES; METABOLIC SYNDROME X; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 33744484530     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302006000200017     Document Type: Review

References (53)

1. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999;33:1004-10.
2. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003;26(suppl 1):S33-S50.
3. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-24.
4. Bennett PH, Haffner S, Kasiske BL, Keane WF, Mogensen CE, Parving HH, et al. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis 1995;25:107-12.
5. Houlihan CA, Tsalamandris C, Akdeniz A, Jerums G. Albumin to creatinine ratio: a screening test with limitations. Am J Kidney Dis 2002;39:1183-9.
6. Schwab SJ, Dunn FL, Feinglos MN. Screening for microalbuminuria. A comparison of single sample methods of collection and techniques of albumin analysis. Diabetes Care 1992;15:1581.
7. Mogensen CE, Vestbo E, Poulsen PL, Christiansen C, Damsgaard EM, Eiskjaer H, et al. Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care 1995;18:572-81.
8. Pegoraro AA, Peracha W, Hasnain M, Ranginwala N, Shaykh M, Singh AK, et al. Evaluation of a new fluorescent dye method to measure urinary albumin in lieu of urinary total protein. Am J Kidney Dis 2000;35:739-44.
9. Valmadrid C, Klein R, Moss SE, Klein BE. The risk of cardiovascular mortality associated with microalbuminuria and gross proteinuria in persons with older onset diabetes mellitus. Arch Intern Med 2000;160:1093-8.
10. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications; estimates and projections to the year 2010. Diabet Med (England) 1997;14(suppl 5):S1-S85.
11. Hollenberg NK. ACE inhibition, angiotensin II receptor blockade and diabetic nephropathy. In: Mogensen CE, editor. The kidney and hypertension in diabetes mellitus. Boston:Kluwer Academic Publishers, 2000. p.417-22.
12. Langham RG, Kelly DJ, Cox AJ, Thomson NM, Holthofer H, Zaoui P, et al. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 2002;45:1572-6.
13. Wolf G. Angiotensin II is involved in the progression of renal disease: importance of non-hemodynamic mechanisms. Nephrologie 1998;19:451-6.
14. Ayo SH, Radnik RA, Garoni J, Glass II WF, Kreisberg JI. High glucose causes an increase in extracellular matrix proteins in cultured mesangial cells. Am J Pathol 1990;136:1339-48.
15. McLennan SV, Fisher EJ, Yue DK, Turtle JR. High glucose concentration causes a decrease in mesangium degradation: a factor in the pathogenesis of diabetic nephropathy. Diabetes 1994;43:1041-5.
16. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996;27:2033-9.
17. Hockensmith ML, Estacio RO, Mehler P, Havranek EP, Ecder ST, Lundgren RA, et al. Albuminuria as a predictor of heart failure hospitalizations in patients with type 2 diabetes. J Card Fail 2004;10:126-31.
18. Schmitz A, Vaeth M. Microalbuminuria: a major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients. Diabet Med 1988;5:126-34.
19. Tuttle KR, Puhlman ME, Cooney SK, Short R. Urinary albumin and insulin as predictors of coronary artery disease: an angiographic study. Am J Kidney Dis 1999;34:918-25.
20. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999;19:1992-7.
21. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-6.
22. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003;139:901-6.
23. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001;37:1053-9.
24. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1984;310:356-60.
25. Esmail ZN, Loewen PS. Losartan as an alternative to ACE inhibitors in patients with renal dysfunction. Ann Pharmacother 1998;32:1096-8.
26. Parving HH. Diabetic nephropathy: prevention and treatment. Kidney Int 2001;60:2041-55.
27. Deckert T. Nephropathy and coronary death. The fatal twins in diabetes mellitus. Nephrol Dial Transplant 1994;9:1069-71.
28. Chobanian AV, Bakris GL, Black HR, Cushman WC. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. Hypertension 2003;42:1206-52.
29. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646-61.
30. Klausen KP, Scharling H, Jensen G, Jensen JS. New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension 2005;46:33-7.
31. Wang TJ, Evans JC, Meigs JB, Rifai N, Fox CS, D'Agostino RB, et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation 2005;111:1370-6.
32. Yokoyama H, Tomonaga O, Hirayama M, Ishii A, Takeda M, Babazono T, et al. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin converting enzyme inhibitors in NIDDM patients. Diabetologia 1997;40:405-11.
33. Parving HH, Hommel E, Mathiesen ER. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. BMJ 1988;296:156-60.
34. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983;1:1175-9.
35. Parving HH, Smidt UM, Hommel E, Mathiesen ER, Rossing P, Nielsen F, et al. Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis 1993;22:188-95.
36. Hypertension in Diabetes Study (HDS). I- Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications; II. Increased risk of cardiovascular complications in hypertensive type-2 diabetic patients. J Hypertens 1993;11:307-17.
37. Adler A, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-9.
38. UK prospective Diabetes Study Group. Tight blood pressure control and risk of microvascular and macrovascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
39. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principle results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-62.
40. Björk S. The renin angiotensin system in diabetes mellitus: a physiological and therapeutic study. Scand J Urol Nephrol 1990;126(suppl):1-50.
41. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional immunohistochemical and molecular biological correlations. Am J Physiol 1993;265:F477-86.
42. Zatz R, Dunn BR, Meyer TW, Anderson S, RennKe GH, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-30.
43. Deray G. Do antagonists of angiotensin II AT1 receptors protect the kidney? Arch Mal Coeur Vaiss 1999;92:903-7.
44. Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z. Irbesartan normalizes the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001;44:874-7.
45. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in the rat glomerular mesangial cells. J Clin Invest 1994;93:2431-7.
46. Wolf G, Ziyadeh FN. The role of angiotensin II in diabetic nephropathy: emphasis on non-hemodynamic mechanisms. Am J Kidney Dis 1997;29:153-63.
47. Singh R, Alavi N, Singh AK, Leehey DJ. Role of angiotensin II in glucose induced inhibition of mesangial matrix degradation. Diabetes 1999;48:2066-73.
48. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al; the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med 2001;345:861-9.
49. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al; The Collaborative Study Group. Renoprotective effect of the angiotensin receptor antagonist irbersartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 2001;345:851-60.
50. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen R, Arner P; the Irbersartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbersartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Eng J Med 2001;345:870-8.
51. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria Kidney Int 2005;68:1190-8.
52. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al; Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-61.
53. Mogensen CE, Neldam S, Tikkanen I. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.